Five-Part Pentameric Nanocomplex Shows Improved Efficacy of Doxorubicin in CD44+ Cancer Cells

ACS Omega
Nathan BealsSoumitra Basu

Abstract

The CD44 receptor is common among many cancer types where overexpression is synonymous with poor prognosis in prostate, glioma, and breast cancer. More notably CD44 overexpression has been shown in a number of different cancer stem cells (CSC) which are present in many solid tumors and drive growth, recurrence, and resistance to conventional therapies. Triple negative breast cancer CSCs correlate to worse prognosis and early relapse due to higher drug resistance and increased tumor heterogeneity and thus are prime targets for anticancer therapy. To specifically target cells overexpressing CD44 receptors, including CSCs, we synthesized a pentameric nanocomplex (PNC) containing gold nanoparticles, doxorubicin (Dox) conjugated to thiolated hyaluronic acid via an acid-labile hydrazone bond, and thiolated poly(ethylene glycol) DNA CD44 aptamer. In vitro drug release was highest at 8 h time point at acidic pH (pH 4.7) and in 10 mM glutathione. The PNC is almost an order of magnitude more effective than Dox alone in CD44+ cells versus CD44 low cells. Functionally, the PNC reduced CSC self-renewal. The PNC provides a therapeutic strategy that can improve the efficiency of Dox and decrease nontargeted toxicity thereby prolonging its use...Continue Reading

References

Mar 1, 1990·Journal of Biochemical and Biophysical Methods·J M CampbellE Wickstrom
Jul 1, 1993·The Journal of Cell Biology·R J PeachA Aruffo
Sep 30, 1999·Bioconjugate Chemistry·Y Luo, G D Prestwich
Jun 28, 2001·International Journal of Pharmaceutics·B Szachowicz-PetelskaW Lewandowski
Jan 4, 2003·Nature Reviews. Molecular Cell Biology·Helmut PontaPeter A Herrlich
Jul 28, 2004·Langmuir : the ACS Journal of Surfaces and Colloids·M V KitaevaA A Yaroslavov
Apr 12, 2006·Proceedings of the National Academy of Sciences of the United States of America·Omid C FarokhzadRobert Langer
Jul 31, 2007·Advanced Drug Delivery Reviews·Lisa M Bareford, Peter W Swaan
Sep 25, 2007·Nature Biotechnology·Hak Soo ChoiJohn V Frangioni
Oct 1, 2008·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Anekant Jain, Sanjay K Jain
Apr 7, 2009·Nano Letters·Steven D PerraultWarren C W Chan
May 19, 2009·Nanomedicine : Nanotechnology, Biology, and Medicine·Anekant JainAadil M Beg
Jul 17, 2009·Advanced Materials·Sulin ZhangSubra Suresh
Sep 17, 2010·Biochemistry·Anoma SomasunderamDavid G Gorenstein
Oct 12, 2010·Nanoscale·Yiwei Teow, Suresh Valiyaveettil
Dec 21, 2010·Journal of Nanoparticle Research : an Interdisciplinary Forum for Nanoscale Science and Technology·Alaaldin M Alkilany, Catherine J Murphy
Apr 26, 2011·Journal of Controlled Release : Official Journal of the Controlled Release Society·Glenn D Prestwich
Jul 7, 2011·Langmuir : the ACS Journal of Surfaces and Colloids·Dorota Bartczak, Antonios G Kanaras
Oct 20, 2011·The British Journal of Radiology·S JainJ M O'Sullivan
Mar 29, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Otto Metzger-FilhoMartine Piccart-Gebhart
Apr 14, 2012·Journal of Amino Acids·Volodymyr I Lushchak
May 23, 2012·Nature Chemistry·Hannu Häkkinen
Jun 14, 2012·Clinical & Developmental Immunology·Appalaraju Jaggupilli, Eyad Elkord
Jul 28, 2012·Therapeutic Delivery·Erik C DreadenMostafa A El-Sayed
Oct 4, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F André, C C Zielinski
Nov 1, 2012·Journal of Clinical Pathology·Francisco Ferro de BeçaFernando Schmitt
Aug 2, 2013·Nucleic Acid Therapeutics·Roejarek KanjanawarutSu XiaoDi
Sep 17, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Vatsal ShahTamara Minko
Sep 21, 2013·Nature·Corbin E Meacham, Sean J Morrison

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
electrophoresis
dynamic light scattering
NMR
infrared spectrometry
Assay
Fluorescence Microscopy
flow cytometry

Software Mentioned

Image J

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Breast Cancer: Therapeutic Approaches

Several different therapeutic approaches are used to treat breast cancer. These include chemotherapy, hormonal therapy, targeted therapy, and Immunotherapy. Discover the latest research on breast cancer therapeutic approaches here.

Breast Cancer: Chemo-Resistance

Some cancers are difficult to treat and aggressive including the "triple-negative" breast cancer. This type of cancer is chemoresistant even before chemotherapy begins. Here are the latest discoveries chemo-resistance in breast cancer.